Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $213.00 by Analysts at Bank of America

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) had its price target lifted by equities researchers at Bank of America from $166.00 to $213.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s target price points to a potential upside of 32.53% from the company’s current price.

Several other equities research analysts have also recently commented on SRPT. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research note on Tuesday, May 14th. Mizuho lifted their target price on Sarepta Therapeutics from $145.00 to $179.00 and gave the company a “buy” rating in a research note on Friday, May 17th. JPMorgan Chase & Co. lowered their target price on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Piper Sandler began coverage on Sarepta Therapeutics in a research note on Friday, May 31st. They issued an “overweight” rating and a $157.00 target price for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $177.65.

Read Our Latest Stock Report on SRPT

Sarepta Therapeutics Trading Up 30.1 %

Shares of SRPT opened at $160.72 on Friday. The stock has a fifty day moving average price of $125.56 and a two-hundred day moving average price of $119.95. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a market cap of $15.19 billion, a price-to-earnings ratio of 1,461.09 and a beta of 0.96.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same quarter in the previous year, the company posted ($1.44) EPS. The business’s revenue for the quarter was up 63.1% compared to the same quarter last year. Analysts predict that Sarepta Therapeutics will post 2.99 EPS for the current fiscal year.

Insider Activity

In other news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of SRPT. Principal Securities Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $26,000. Mather Group LLC. bought a new stake in Sarepta Therapeutics during the first quarter worth about $28,000. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 154 shares in the last quarter. Finally, New Covenant Trust Company N.A. bought a new stake in Sarepta Therapeutics during the first quarter worth about $32,000. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Further Reading

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.